Kamada Receives Final FDA Approval to Commence Phase III Clinical Trials of API with Congenital Emphysema Patients (Business Wire via Yahoo! Finance)
REHOVOT, Israel----March 9, 2006--Kamada , a bio-pharmaceutical company which develops, manufactures and markets prescription drugs, today announced the crossing of a major milestone on its API roadmap with the FDA announcing the removal of the "Clinical Hold" status.